Press Releases
Valiltramiprosate is an investigational agent and not approved for use anywhere in the world. Statements in news stories may be aspirational.
Alzheon Announces Presentations at Two Upcoming Investor Conferences
FRAMINGHAM, Mass., November 12, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, [...]
Alzheon Announces Efficacy Outcomes from Two Prior Tramiprosate Phase 3 Studies
Patients with Mild to Moderate Alzheimer’s Disease and APOE4/4 Genotype ShowedRobust and Sustained Efficacy on Cognitive and Functional Co‐Primary Outcomes over 78 weeks with Favorable Safety [...]
Alzheon Announces Initiation of Clinical Studies with ALZ‐801 Bridging to Pivotal Phase 3 Study in Alzheimer’s Disease
Phase 1b Multiple Dose‐Ranging Study and Tablet Bioequivalence Study Will Provide Clinical Dose and Tablet Formulation Data to Support ALZ‐801 Phase 3 Program FRAMINGHAM, Mass., November [...]
Alzheon Appoints Susan Abushakra, M.D., as Chief Medical Officer
FRAMINGHAM, Mass., September 9, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological [...]
Alzheon Establishes New Corporate Headquarters
Expanded Facility Supports Business and Clinical Operations to Drive Future Pivotal Study of ALZ-801 in Patients with Alzheimer’s Disease FRAMINGHAM, Mass., April 8, 2015 -- Alzheon, [...]
Alzheon Announces $10 Million Series A Financing
Funding to Advance ALZ-801 Toward a Pivotal Clinical Study in Alzheimer’s Disease FRAMINGHAM, Mass., April 8, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on [...]
Alzheon Announces Phase 1 Results of ALZ-801, a First-in-Class Inhibitor of Amyloid Formation and Neurotoxicity for Alzheimer’s Disease
Phase 1 data demonstrated superior properties for ALZ-801 as an optimized prodrug of tramiprosate Clinical program for ALZ-801 supported by expanded post-hoc Phase 3 analyses with tramiprosate [...]
Alzheon Announces Patent Allowance in Europe for ALZ-801 in Development for Alzheimer’s Disease
LEXINGTON, Mass., January 5, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the European Patent Office [...]
Alzheon Appoints David Nikodem, Ph.D., to Board of Directors
LEXINGTON, Mass., January 5, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that David Nikodem, Ph.D., has joined [...]
Alzheon Announces Patent Issuance in Japan for ALZ-801 in Development for Alzheimer’s Disease
LEXINGTON, Mass., September 5, 2014 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the Japan Patent Office [...]
Newsletter
Sign up for updates
Get the latest Alzheon news in your inbox.
Not seeing the signup form? An ad or privacy blocker may be hiding it – email info@alzheon.com and we’ll add you to the list.
